62 Spam-Free Article(s) Found
Sort:
Relevance
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
LLY Eli Lilly and Company $105.71 $113.53B Sell
Article Searches
Company News For Jan 22, 2019 http://www.zacks.com/stock/news/348839/company-news-for-jan-22-2019?cid=CS-ZC--348839 Jan 22, 2019 - Companies In The News Are: TIF,LLY,KSU,JBHT
Does Johnson & Johnson's Grim Outlook Spell Trouble for Big Pharma Stocks? https://www.fool.com/investing/2019/01/24/does-johnson-johnsons-grim-outlook-spell-trouble-f.aspx?source=iedfolrf0000001 Jan 24, 2019 - Here's why comments from J&J executives about the future of pharmaceuticals made investors so nervous.
Pharma Stock Roundup: JNJ & BMY's Q4 Earnings, Study Failures at LLY & ABBV http://www.zacks.com/stock/news/349786/pharma-stock-roundup-jnj-bmys-q4-earnings-study-failures-at-lly-abbv?cid=CS-ZC-FT-349786 Jan 25, 2019 - J&J (JNJ) and Bristol-Myers (BMY) kick off earnings for pharma sector. Lilly (LLY) and AbbVie (ABBV) announce failure of late-stage studies.
Lilly (LLY) Hits 52-Week High, Can the Run Continue? http://www.zacks.com/stock/news/351514/lilly-lly-hits-52-week-high-can-the-run-continue?cid=CS-ZC-FT-351514 Feb 01, 2019 - Lilly (LLY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Allergan Stock Falls as FDA OK's Botox Rival for Frown Lines http://www.zacks.com/stock/news/352006/allergan-stock-falls-as-fda-oks-botox-rival-for-frown-lines?cid=CS-ZC-FT-352006 Feb 05, 2019 - Allergan's (AGN) stock declines almost 4% after FDA approves Evolus' Jeuveau injection to treat frown lines, which can pose strong competition to Botox.
Sanofi's Myeloma Candidate Meets Goal in Phase III Study http://www.zacks.com/stock/news/352133/sanofis-myeloma-candidate-meets-goal-in-phase-iii-study?cid=CS-ZC-FT-352133 Feb 05, 2019 - Sanofi's (SNY) late-stage candidate, isatuximab, achieves the primary endpoint in a pivotal study by prolonging progression free survival in patients with relapsed/refractory multiple myeloma.
Eli Lilly and Company (LLY) CEO Dave Ricks on Q4 2018 Results - Earnings Call Transcript https://seekingalpha.com/article/4238673-eli-lilly-company-lly-ceo-dave-ricks-q4-2018-results-earnings-call-transcript?source=feed_sector_healthcare Feb 06, 2019 -
Eli Lilly & Co (LLY) Q4 2019 Earnings Conference Call Transcript https://www.fool.com/investing/2019/02/06/eli-lilly-co-lly-q4-2019-earnings-conference-call.aspx?source=iedfolrf0000001 Feb 06, 2019 - LLY earnings call for the period ending December 31, 2018.
Pharma Stock Roundup: Q4 Earnings at MRK, LLY, CHMP Nod for Several Drugs http://www.zacks.com/stock/news/353203/pharma-stock-roundup-q4-earnings-at-mrk-lly-chmp-nod-for-several-drugs?cid=CS-ZC-FT-353203 Feb 08, 2019 - Merck (MRK) and Lilly (LLY) report Q4 results. CHMP gives nod to several drugs.
Incyte Down as FDA Extends Review Period of Jakafi for GVHD http://www.zacks.com/stock/news/353405/incyte-down-as-fda-extends-review-period-of-jakafi-for-gvhd?cid=CS-ZC-FT-353405 Feb 08, 2019 - The FDA extends the review period of Incyte's (INCY) sNDA for the label expansion of Jakafi for the treatment of acute GVHD.

Pages: 1234567

Page 1>